Gossamer Bio submitted a New Drug Application (NDA) for its seralutinib treatment.
3 reports, 2 independent
Updated Fri 00:00
No new developments lately
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gossamer Bio submitted a New Drug Application (NDA) for its seralutinib treatment.